Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACTICS-L Phase II TACE plus lenvatinib in unresectable HCC
jRCTs031180074Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenvatinib in hepatocellular carcinoma (HCC), sponsored by Eisai Co., Ltd. Primary endpoint: Progression-free survival. Started Feb 2019; status: completed.
02
Drugs
lenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCTs031180074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180074.